Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Biorestorative Therapies, Inc. (BRTX) vs PMGC Holdings Inc. (ELAB)

Biorestorative Therapies, Inc. and PMGC Holdings Inc. are both Biotechnology companies. Biorestorative Therapies, Inc. and PMGC Holdings Inc. are of similar size ($3.7M and $3.5M). PMGC Holdings Inc. grew revenue faster over the last twelve months: 5.41% against −8.47%. PMGC Holdings Inc. has the higher net margin (−523.0% vs −3,089.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, PMGC Holdings Inc. leads on 11 and Biorestorative Therapies, Inc. on 6.

Valuation

Metric BRTX ELAB Biotechnology median
P/E n/m n/m 7.88
P/S 6.32 0.85 11.47
P/B 0.75 0.13 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.09 1.45 0.74
EV/Sales (3.60) (6.33) 10.73
Earnings yield (839.22%) (23,768.66%) (28.84%)
Free cash flow yield (579.97%) (411.61%) (23.03%)

Profitability

Metric BRTX ELAB Biotechnology median
Gross margin 92.09% 31.08% 65.16%
Operating margin (3,974.66%) (458.63%) 0.00%
Net margin (3,089.30%) (522.99%) 0.00%
Free cash flow margin (3,302.04%) (348.69%) 0.00%
Return on equity (241.50%) (104.60%) (57.72%)
Return on assets (147.75%) (58.71%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BRTX ELAB Biotechnology median
Revenue growth (TTM) (8.47%) 5.41% 5.64%
EPS growth (last fiscal year) (36.21%) 94.22% —
Revenue growth, 5-year CAGR 36.11% — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric BRTX ELAB Biotechnology median
Debt to equity 0.00 0.02 0.00
Current ratio 2.35 1.36 4.73
Net debt to EBITDA 0.19 0.87 0.96

Dividend

Metric BRTX ELAB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric BRTX ELAB Biotechnology median
Market cap 3.47m 3.66m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack